SABCS: PD 0332991 + letrozole studied in ER+ breast cancer
(HealthDay)—For women with estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer, the investigational agent PD 0332991 plus letrozole improves progression-free survival versus ...
Dec 5, 2012
0
0